European Medicines Agency (EMA) European Medicines Agency (EMA) and European Alliance of Associations for Rheumatology (EULAR) bilateral meeting Online European Medicines Agency, Amsterdam, the Netherlands Start date: 18 March 2026, 14:00 (CET)
European Medicines Agency - Wikipedia The EMA was founded after more than seven years of negotiations among EU governments and replaced the Committee for Proprietary Medicinal Products and the Committee for Veterinary Medicinal Products, though both of these were reborn as the core scientific advisory committees
欧盟简介及欧洲药物管理局（EMA）官网介绍 - 知乎 欧盟药品监管机构，即欧洲药品管理局 (European Medicines Agency，简称EMA)，其前身 (2004年前)为欧洲药品评价局 (European Agency for the Evaluation of Medical Products，简称 EMEA)，于1993年依法成立，自1995年开始正式受理欧盟各成员国人用和兽用专卖药品的上市申请。
EMA IRIS 2025-2026: Key updates and what MAHs need to know The European Medicines Agency (EMA) launched the IRIS platform in 2018 to streamline orphan designation procedures Since its introduction, IRIS has progressively expanded to encompass a broader range of regulatory and scientific activities, supporting structured and transparent communication between the Agency and Market Authorisation Holders (MAHs) Since 2020, it has provided a platform for
CTIS for sponsors - EMA The sponsor workspace in the Clinical Trials Information System (CTIS) assists clinical trial sponsors and other organisations involved in running clinical trials in preparing and compiling clinical trial applications and dossiers to submit for assessment by Member States in the European Union (EU) and European Economic Area (EEA) The revised CTIS transparency rules became applicable on 18
What is European Medicines Agency (EMA)? - The Pharmadaily The European Medicines Agency (EMA) is a prominent regulatory authority that plays a pivotal role in the evaluation, supervision, and authorization of medicinal products within the European Union (EU) and European Economic Area (EEA)
EMA launches tools to accelerate development of medicines The European Medicines Agency (EMA) has launched three major new features of PRIME, the Agency’s scheme to enhance support for the development of medicines targeting an unmet medical need